Search tool

These are the EMCDDA's final annual accounts for the financial year 2015.

In this issue: European Drug Report 2016 highlights | Return of MDMA | Rises in overdose deaths | Health responses to new psychoactive substances | Gold medal for EMCDDA | World hepatitis...

While prevalence levels of NPS use remain low in the general European population, there are important concerns with more problematic forms of use and harms. This short report provides an overview of...

The emergence of new psychoactive substances (NPS) over the last decade has posed a major challenge to drug policy. While the limited available data indicates that prevalence levels of NPS use are...

The General Report of Activities is an annual publication providing a detailed progress report of the EMCDDA’s activities over a 12-month period. It catalogues the Centre’s achievements in each area of its...

In September 2015, the EMCDDA and Europol examined the available information on a new psychoactive substance N -phenyl- N -[1-(2-phenylethyl)piperidin-4-yl]acetamide (acetylfentanyl), through a joint assessment. The two organisations concluded that sufficient information...

Comorbidity of substance use and mental health disorders refers to the co-occurrence of a substance use disorder and another mental health disorder in the same individual. In Europe, the presence of psychiatric...

This brochure provides an overview of the 2016 European Drug Report package and includes brief summaries of the four new additions to the Perspectives on drugs (PODs) series.

The Trends and Developments report presents a top-level overview of the drug phenomenon in Europe, covering drug supply, use and public health problems as well as drug policy and responses. Together with...

Transmitted through the sharing of needles, syringes and other injecting equipment, hepatitis C is the most common infectious disease among injecting drug users in Europe today.In this analysis, the EMCDDA looks at...